Antiplatelet drugs / Dipyridamole
Cyclic nucleotide phosphorylase inhibitor
DIPYRIDAMOLE
- vasodilator that:
- inhibits cyclic nucleotide phosphodiesterase 3 (PDE3):
-
cAMP inhibits degranulation
-
PDE3 degrades cAMP (decreasing intracellular cAMP concentrations) resulting in increased degranulation, i.e, PDE inhibits the inhibition of degranulation
-
DIPYRIDAMOLE inhibits PDE3 (increasing intracellular cAMP) resulting in decreased degranulation; i.e, DIPYRIDAMOLE inhibits the inhibition of the inhibition of degranulation)
-
- inhibits adenosine uptake via A2 receptors
- inhibits cyclic nucleotide phosphodiesterase 3 (PDE3):
- negligible clinical value when given alone
- does not influence prothrombin time or activity (does NOT increase bleeding)
- negligible side effects (dizziness, headache, rash)
- in combination with WARFARIN; effectively prevents embolization from prosthetic heart valves
- in combination with ASPIRIN; prolongs platelet survival in thrombotic disease